Evidence map›Paper›PMID 27477907›Full record

ArticleMolecular cell2016

Engineered Covalent Inactivation of TFIIH-Kinase Reveals an Elongation Checkpoint and Results in Widespread mRNA Stabilization.

Juan B Rodríguez-Molina, Sandra C Tseng, Shane P Simonett, Jack Taunton, Aseem Z Ansari

Abstract read
In one paragraph

Article in Molecular cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Coordination of rhythmic RNA synthesis and degradation orchestrates 24- and 12-h RNA expression patterns in mouse fibroblasts.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  12. Article
  13. Systematic Design of Adenosine Analogs as Inhibitors of aJournal of medicinal chemistry · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juan B Rodríguez-MolinaDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.
Sandra C TsengDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.
Shane P SimonettDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA.
Jack TauntonDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, USA.
Aseem Z AnsariDepartment of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA; The Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI 53706, USA. Electronic address: azansari@wisc.edu.

Funding

Research Training for Computation and Informatics in Biology and MedicineT15LM007359 · NLM · UNIVERSITY OF WISCONSIN-MADISON · PI Mark W. Craven, Colin Noel Dewey · 2002 to 2026
$22.6M
GRADUATE TRAINING IN MOLECULAR BIOSCIENCEST32GM007215 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI HULL, CHRISTINA M · 1985 to 2018
$22.5M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008349 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI FOX, BRIAN G · 1989 to 2019
$22.5M
Institutional Training in the Genomic SciencesT32HG002760 · NHGRI · UNIVERSITY OF WISCONSIN-MADISON · PI Qiongshi Lu · 2003 to 2026
$17.7M
Deciphering the molecular and physiological cues that guide CTD patterning by Bur1/Cdk9R01GM117362 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI ANSARI, ASEEM Z · 2016 to 2019
$1.3M
Highly Selective, Irreversible Protein Kinase InhibitorsR01GM071434 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAUNTON, JACK · 2005 to 2008
$1.1M
NHGRI NIH HHS T32 HG002760NIGMS NIH HHS R01 GM071434NIGMS NIH HHS R01 GM117362NIGMS NIH HHS T32 GM007215NIGMS NIH HHS T32 GM008349NLM NIH HHS T15 LM007359
6 · The paper itself

Abstract

During transcription initiation, the TFIIH-kinase Kin28/Cdk7 marks RNA polymerase II (Pol II) by phosphorylating the C-terminal domain (CTD) of its largest subunit. Here we describe a structure-guided chemical approach to covalently and specifically inactivate Kin28 kinase activity in vivo. This method of irreversible inactivation recapitulates both the lethal phenotype and the key molecular signatures that result from genetically disrupting Kin28 function in vivo. Inactivating Kin28 impacts promoter release to differing degrees and reveals a "checkpoint" during the transition to productive elongation. While promoter-proximal pausing is not observed in budding yeast, inhibition of Kin28 attenuates elongation-licensing signals, resulting in Pol II accumulation at the +2 nucleosome and reduced transition to productive elongation. Furthermore, upon inhibition, global stabilization of mRNA masks different degrees of reduction in nascent transcription. This study resolves long-standing controversies on the role of Kin28 in transcription and provides a rational approach to irreversibly inhibit other kinases in vivo.

Indexed as

Protein EngineeringRNA StabilityTranscription Elongation, GeneticCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesDNA Polymerase IIHumansModels, MolecularMutationNucleosomesPhosphorylationPromoter Regions, GeneticProtein ConformationProtein Kinase InhibitorsRNA, FungalRNA, MessengerCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesDNA Polymerase IIKin28 protein kinase, S cerevisiaeNucleosomesProtein Kinase InhibitorsRNA, FungalRNA, MessengerSaccharomyces cerevisiae Proteins

Identifiers

PMID27477907
PMCPMC5122673

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.